A Huntington disease re s e a rc h
Research Round-up Lise Munsie overviews recent developments in
HD basic research, imaging, and clinical research. Page 3
World Congress on HD: Melbourne, Australia Dr. Mahmoud Pouladi recaps highlights from this year's international meeting of world researchers in HD. Page 4
Meet the Investigator Lead TRACK-HD investigator Sarah Tabrizi shares her thoughts on the most promising basic research in HD. Page 5
HD Insights periodical Issue No 1 -- Fall 2011
Status Report: Clinical Trials At a glance -- information on current clinical trials in HD. Page 8
Meet the Company Prana Biotechnology CEO Geoffrey Kempler discusses the potential for PBT2 to improve cognition in Huntington disease. Page 9
By: Emily Fisher and Alicia Semaka
There are two ways to answer the question "how many people have Huntington disease (HD)?" The first is by determining the prevalence (i.e., the proportion of a population that has a given condition at a particular point in time), and the second is by determining the incidence (i.e., the number of people who will develop a condition over a defined period of time) of HD. Prevalence answers the question of "how many people currently have HD?" and incidence answers the question of "how frequently are people being diagnosed with HD?" Research suggests that the answers to both of these questions are changing and perhaps increasing. These changes will have important biological, economic, and social implications for the future. (continued on Page 2...)
HD InsightsTM, Vol. 1
TM
How Many People Have Huntington Disease? Figure 1: Minimum Prevalence of HD Globally
Warby et al. 2009. Additional references may be viewed at http://www.hdinsights.org/Publications.html
Copyright © Huntington Study Group 2011. All rights reserved.
1
